Canagliflozin and dapagliflozin, two commonly used SGLT2 inhibitors, have been found to inhibit cancer cell proliferation and metabolic reprogramming through various mechanisms, including downregulating the Wnt/β-catenin pathway, inhibiting oxidative phosphorylation, activating AMPK, inducing ferroptosis, and suppressing mTOR. Here, SLC5A2 is linked to cancer.